Novel CTC Culture Method Developed to Study Metastatic Cancer
|
By LabMedica International staff writers Posted on 26 Oct 2020 |

Image: Circulating tumor cells (CTCs) are cancer cells that are released and disseminated into the bloodstream and lymphatic system. CTC cultures were successfully propagated from breast epithelial cells (Photo courtesy of Menarini Silicon Biosystems).
Cancer metastasis is responsible for most cancer-associated death. During metastasis, cells that escape the primary tumor into the circulatory system are known as circulating tumor cells (CTCs).
Circulating tumor cells represent a unique population of cells that can be used to investigate the mechanistic underpinnings of metastasis. Unfortunately, current technologies designed for the isolation and capture of CTCs are inefficient. Existing literature for in vitro CTC cultures report low (6% to 20%) success rates.
Scientists from Georgetown University Medical Center (Washington, DC, USA) enrolled from 12 metastatic breast cancer patients representing all three major subtypes, HER2 positive, hormone receptor positive, and triple negative and samples from five healthy donors. After collecting a patient's blood sample, the team removed red blood cells (RBCs) and granulocytes using gradient centrifugation. They then harvest the rest of the cells, including CTCs, and put them into a custom cell culture growth medium for culture, followed by downstream analysis.
To see whether they had indeed cultured CTCs, the group then tested for the presence of epithelial, mesenchymal, and breast tissue markers to establish the cells' tissue of origin using reverse-transcriptase quantitative polymerase chain reaction (qRT-PCR). They selected cytokeratin 5 and 8 and mammaglobin and successfully identified all three biomarkers in all 12 cultures. The team then used RNA-seq on the six samples that yielded sufficient RNA and could be cultured for more than 30 days in order to characterize their gene expression. These six samples all contained CD45+ leukocytes, they noted, which have previously been shown to support CTC survival.
Overall, the investigators identified 7,234 genes that were significantly differentially expressed in the CTCs-containing samples compared to the healthy donors. Increased expression of multiple genes was correlated with a significant drop in overall patient survival, they found. Using multiple bioinformatics tools to confirm that the CTCs in the samples originated from the cancers, the team identified 52 significantly enriched key cancer pathways and 21 enriched genes that are important to breast cancer progression and metastasis. The group mainly found enriched CD8 T cells, neutrophils, and macrophages in the CTC cultures and noted that the isolation technique appeared to favor the survival of macrophages and neutrophils.
Seema Agarwal, PhD, the senior author and associate professor of pathology, said, “We could take DNA and RNA from cultured CTCs and do a detailed genomic analysis that can be done very quickly in a more meaningful way, as prior to expansion, there are very few CTCs in the patient's blood. We don't know whether the cultured cells represent the heterogeneity of the CTCs, but as we move forward, we hope to characterize the heterogeneity of the cells.”
The authors concluded that once profiled, CTCs can provide a significant amount of information based solely on their identity as an intermediary stage of metastasis. Comparison of CTCs with primary tumors would enable the identification of metastatic drivers and lead to the development of metastasis-preventing therapies. Thus, having a standardized method for the capture and culture of CTCs is a pressing need. The study was published on September 28, 2020 in the journal Cancers.
Related Links:
Georgetown University Medical Center
Circulating tumor cells represent a unique population of cells that can be used to investigate the mechanistic underpinnings of metastasis. Unfortunately, current technologies designed for the isolation and capture of CTCs are inefficient. Existing literature for in vitro CTC cultures report low (6% to 20%) success rates.
Scientists from Georgetown University Medical Center (Washington, DC, USA) enrolled from 12 metastatic breast cancer patients representing all three major subtypes, HER2 positive, hormone receptor positive, and triple negative and samples from five healthy donors. After collecting a patient's blood sample, the team removed red blood cells (RBCs) and granulocytes using gradient centrifugation. They then harvest the rest of the cells, including CTCs, and put them into a custom cell culture growth medium for culture, followed by downstream analysis.
To see whether they had indeed cultured CTCs, the group then tested for the presence of epithelial, mesenchymal, and breast tissue markers to establish the cells' tissue of origin using reverse-transcriptase quantitative polymerase chain reaction (qRT-PCR). They selected cytokeratin 5 and 8 and mammaglobin and successfully identified all three biomarkers in all 12 cultures. The team then used RNA-seq on the six samples that yielded sufficient RNA and could be cultured for more than 30 days in order to characterize their gene expression. These six samples all contained CD45+ leukocytes, they noted, which have previously been shown to support CTC survival.
Overall, the investigators identified 7,234 genes that were significantly differentially expressed in the CTCs-containing samples compared to the healthy donors. Increased expression of multiple genes was correlated with a significant drop in overall patient survival, they found. Using multiple bioinformatics tools to confirm that the CTCs in the samples originated from the cancers, the team identified 52 significantly enriched key cancer pathways and 21 enriched genes that are important to breast cancer progression and metastasis. The group mainly found enriched CD8 T cells, neutrophils, and macrophages in the CTC cultures and noted that the isolation technique appeared to favor the survival of macrophages and neutrophils.
Seema Agarwal, PhD, the senior author and associate professor of pathology, said, “We could take DNA and RNA from cultured CTCs and do a detailed genomic analysis that can be done very quickly in a more meaningful way, as prior to expansion, there are very few CTCs in the patient's blood. We don't know whether the cultured cells represent the heterogeneity of the CTCs, but as we move forward, we hope to characterize the heterogeneity of the cells.”
The authors concluded that once profiled, CTCs can provide a significant amount of information based solely on their identity as an intermediary stage of metastasis. Comparison of CTCs with primary tumors would enable the identification of metastatic drivers and lead to the development of metastasis-preventing therapies. Thus, having a standardized method for the capture and culture of CTCs is a pressing need. The study was published on September 28, 2020 in the journal Cancers.
Related Links:
Georgetown University Medical Center
Latest Technology News
- New qPCR Master Mixes Offer Broad Compatibility for Routine Research
- Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
- Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
- Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
- AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
- Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows
- New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
- Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
- Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
- New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
- ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
- Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
- New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
- Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Channels
Clinical Chemistry
view channel
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreFDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







